TriangleUniversal Donor (UD) TGFβi NK Cells (NCT06450041)
Universal Donor (UD) TGFβi NK Cells trial for Neuroblastoma (NCT06450041). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged one to thirty-one with high-risk neuroblastoma that relapsed, progressed, or remains refractory or persistent after qualifying induction treatment. Previous progression on the ANBL1221 regimen excludes participation.
The idea: donor NK cells are prepared to resist tumor-related immune suppression. Researchers add them to temozolomide, irinotecan, dinutuximab, and sargramostim. Chemotherapy starts first; NK cells follow on day eight if tolerated. Up to six cycles assess response and safety.
This phase 2 study plans 62 patients. Keri Streby and Mark Ranalli lead at Nationwide Children's, Columbus; eight US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.